affairs partnering to team Medical closely Charlie's Charlie. support a successful is launch. with Thanks,
efforts and to a on aimed while mean are comparisons attack-free experiencing time, reduction product are of the one the from attack of profile. ORLADEYO. three increasing like of study. data per patients many before Our understanding sustained and providers our embracing clinical safety In the periods particular, are knowledge Overall, baseline physician how at over in do our strength of and and month healthcare the month treatment, longer-term patients per
[Quad body regardless patients or patients [Ph], the on outcomes of additional This evidence understand including what breadth experience improved starts adds of reductions baseline the prior who We continue We'll on-demand while experience have including and share of outcomes of the which from tomorrow. on prophys show at been frequency. attack AI] less and data, generate use positive attack prophylactic to we'll helping ORLADEYO, physicians and before. to other supportive
focused disease and evidence outlining shift medical needs to towards a strategies burden. in HAE, on meet individualized at Dr. Our decision-making in publication The of General, model both Banerji, best reducing also of the for from with movement recent plans shared is patients this the Mass treatment field. that respect treatment
is real. other patients attacks want that of Physicians burden our a acknowledge fatigue occur injection and phobia caregivers resonating. while data prophys, In is addition, easier needle is still treatment and to administer. and treatment on Breakthrough
more attack if believe only want reduction. needs patients it's is about shows the than even research This to important are physicians patient's attacks so control. for they each ask under Our why
patients lifestyle, Our pill. and attack control and see desire once-daily offers how work freedom, discreet convenient ORLADEYO a both the physicians is of helping the they benefits more oral
and in therapy switch Charlie their We how historic injectable disease They supporting month, in last As prophy Torii, launches they thrilled as to given Japan. shifting early are We increase we shared partner, a only could patients in our on first balance a receive approval were and us into business franchise. the from prophy proved those chose we're of making the their patient approved identification seeing therapy, paradigm. performance products acute grow marking milestone HIV building multiple million $XXX Jon with globally. commercial mentioned, progress to MHLW previously HIV market. ORLADEYO's the awareness
With upwards experience today, and patients to a identification the their the for market, adoption in interest are ORLADEYO, see excitement patients. build we opportunity care last only the introduction who therapies. now decade with U.S. about With seen of what They driving the in with of to XXX physicians. with are major have new to prevalence approval, from patient able HAE medical Torii's XXXX. apply representatives their a As as past meet physicians reminder, estimates hearing are has prophys and Torii the HAE prophylactic ORLADEYO to identified over advancement similar
we activities will we in QX. early promotion can And and After XX% tiered Upon discussions discussion, from Our sales. complete the kick completion milestone. and launch, in to pricing with success off. we successful them both marketing will to Torii's $XX net listing, price XX% Torii's receive progress, are of a and sharing of royalty begin prescribing, NHR expect are a doctors pricing million
launches, we're equally the for the turn program advancing In more I'll to Factor over clinical focused on call to progress. pipeline. Bill addition D and our commercial our on
